Research Summary:
Alan Baik, MD, is a physician-scientist with clinical expertise in cardio-oncology and inflammatory heart disease. His research program spans basic and translational science, with a focus on chronic hypoxia signaling and adaptation in cardiovascular disease, as well as elucidating the mechanisms of cardiotoxicity that arise from cancer-directed therapies, including targeted therapies and immunotherapies.
The Baik Lab investigates how tissues sense and adapt to chronic low-oxygen states. Our work is centered on identifying novel regulators of hypoxia signaling and translating these discoveries into new insights for cardiovascular and metabolic disorders. By integrating molecular biology, lipid and metabolic profiling, and in vivo physiology inspired by clinical observations, we aim to define how disrupted oxygen sensing contributes to conditions such as heart failure, pulmonary hypertension, lipotoxicity, and cancer therapy-related cardiotoxicity.
Our long-term goal is to leverage cutting edge molecular biology techniques to guide the development of new strategies for preventing and treating diseases driven by chronic hypoxia and dysregulated hypoxia signaling.